Tânia Ogawa Abe

Tânia Ogawa Abe

Auto-generated profile, based on publicly available information

Tânia Ogawa Abe

Programa de Prevenção, Instituto do Coração, Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Tobacco Induced Diseases
Verified
Journal Article
Open access
PGPatricia V. Gaya
Patricia V. Gaya
GFGuilherme Wesley Peixoto da Fonseca
Guilherme Wesley Peixoto da Fonseca
LTLucas Tsuyoshi Tanji
Lucas Tsuyoshi Tanji
TATania O. Abe
Tania O. Abe
MAMaria J N Alves
Maria J N Alves
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
Introduction: High blood pressure in hypertensive smokers is affected by nicotine consumption. This study aimed to evaluate the effect of smoking cessation treatments on blood pressure in hypertensive smokers. Methods: A total of 113 hypertensive smokers on antihypertensives during smoking...

5 April 2018 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
PTPaulo Roberto Xavier Tomaz
Paulo Roberto Xavier Tomaz
JSJuliana Rocha Santos
Juliana Rocha Santos
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
TATânia Ogawa Abe
Tânia Ogawa Abe
PGPatrícia Viviane Gaya
Patrícia Viviane Gaya
PSPaulo Santos
Paulo Santos
The identification of variants in the nicotinic acetylcholine receptor (nAChR) subunit genes associated with smoking phenotypes are increasingly important for prevention and treatment of nicotine dependence. In the context of personalized medicine, the aims of this study were to evaluate whether cholinergic receptor nicotinic alpha 2 (CHRNA2), cholinergic receptor nicotinic alpha 3 (CHRNA3), cholinergic receptor nicotinic alpha 5 (CHRNA5) and cholinergic receptor nicotinic beta 3 (CHRNB3) polymorphisms were associated with nicotine dependence severity, and to investigate possible pharmacogenetics markers of smoking cessation treatment. This study cohort enrolled 1049 smoking patients who received pharmacological treatment (varenicline, varenicline plus bupropion, bupropion plus/or nicotine replacement therapy). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. Fagerström test for nicotine dependence (FTND) and Issa situational smoking scores (Issa score) were analyzed for nicotine dependence. CHRNA2 (rs2472553), CHRNA3 (rs1051730), CHRNA5 (rs16969968 and rs2036527) and CHRNB3 (rs6474413) polymorphisms were genotyped by high resolution melting analysis. Females with GA and AA genotypes for CHRNA5 rs16969968 and rs2036527 polymorphisms had higher success rate in smoking cessation treatment: 44.0% and 56.3% (rs16969968), 41.5% and 56.5% (rs2036527), respectively, compared with carriers of the GG genotypes: 35.7% (rs16969968), 34.8% (rs2036527), (P = 0.03, n = 389; P = 0.01, n = 391). The GA or AA genotypes for the rs16969968 and rs2036527 were associated with higher odds ratio for success in women (OR = 1.63; 95% CI = 1.04 to 2.54; P = 0.03 and OR = 1.59, 95% CI = 1.02 to 2.48; P = 0.04; respectively). We did not find association of these polymorphisms with nicotine dependence related scores. Polymorphisms in the CHRNA2, CHRNA3 and CHRNB3 genes were not associated with the phenotypes studied. CHRNA5 rs16969968 and rs2036527 were associated with higher success rate in the smoking cessation treatment in women. These findings might contribute to advances in personalized medicine.

16 April 2024 in Tobacco Induced Diseases
Verified
Journal Article
Open access
PGPatricia V. Gaya
Patricia V. Gaya
JSJuliana R. Santos
Juliana R. Santos
PTPaulo R. X. Tomaz
Paulo R. X. Tomaz
TATania M. O. Abe
Tania M. O. Abe
MJMiguel Nassif Jr
Miguel Nassif Jr
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
Introduction: Smoking cessation is the best strategy for reducing tobacco-related morbimortality. The goal of this randomized controlled trial was to test whether using the genetically favorable markers to choose a smoking cessation drug treatment (precision medicine) was superior to using the...

6 July 2020 in Genes
Verified
Journal Article
Open access
PDF file
JSJuliana Rocha Santos
Juliana Rocha Santos
PTPaulo Roberto Xavier Tomaz
Paulo Roberto Xavier Tomaz
JAQUELINE RIBEIRO SCHOLZJAQUELINE RIBEIRO SCHOLZ
JAQUELINE RIBEIRO SCHOLZ
PGPatrícia Viviane Gaya
Patrícia Viviane Gaya
TATânia Ogawa Abe
Tânia Ogawa Abe
PSPaulo Santos
Paulo Santos
Introduction: Smoking is considered the leading cause of preventable morbidity and mortality worldwide. Studies have sought to identify predictors of response to smoking cessation treatments. The aim of this study was to analyze a possible association of target gene expression for smoking cessation with varenicline. Methods: We included 74 smokers starting treatment with varenicline. Gene expression analysis was performed through the custom RT² Profiler qPCR array assay, including 17 genes. Times for sample collection were before the start of therapy (T0) and two weeks (T2) and four weeks (T4) after the start of treatment. Results: For gene expression analysis, we selected 14 patients who had success and 13 patients resistant to varenicline treatment. Success was considered to be when a patient achieved tobacco abstinence until the fourth week of treatment and resistant was when a patient had not stopped smoking as of the fourth week of treatment. We observed a significant difference for CHRNA7 gene expression: in the resistant group, samples from T2 and T4 had lower expression compared with T0 (fold change: 0.38, P = 0.007; fold change: 0.67, P = 0.004; respectively). Conclusion: This exploratory clinical study, searching for a possible predictor of effectiveness for varenicline, reaffirmed the association of the α7 nAChR subunit for nicotine dependence and smoking therapy effectiveness with varenicline.